TAILIEUCHUNG - Báo cáo y học: "Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. | Sethi et al. Respiratory Research 2010 11 10 http content 11 1 10 RESPIRATORY RESEARCH RESEARCH Open Access Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease a randomized controlled trial Sanjay Sethi1 Paul W Jones2 Marlize Schmitt Theron3 Marc Miravitlles4 Ethan Rubinstein5 Jadwiga A Wedzicha6 Robert Wilson7 the PULSE Study group Abstract Background Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive pulmonary disease COPD . This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of these exacerbations. Methods Stable patients with COPD were randomized in a double-blind placebo-controlled trial to receive moxifloxacin 400 mg PO once daily N 573 or placebo N 584 once a day for 5 days. Treatment was repeated every 8 weeks for a total of six courses. Patients were repeatedly assessed clinically and microbiologically during the 48-week treatment period and for a further 24 weeks follow-up. Results At 48 weeks the odds ratio OR for suffering an exacerbation favoured moxifloxacin per-protocol PP population N 738 OR 95 confidence interval CI p intent-to-treat ITT population N 1149 OR 95 CI p and a post-hoc analysis of per-protocol PP patients with purulent mucopurulent sputum production at baseline N 323 OR 95 CI p . There were no significant differences between moxifloxacin and placebo in any pre-specified efficacy subgroup analyses or in hospitalization rates mortality rates lung function or changes in St George s Respiratory Questionnaire SGRQ total scores. There was however a significant difference in favour of moxifloxacin in the SGRQ symptom domain ITT vs p PP vs p . Moxifloxacin treatment was not associated with consistent changes in moxifloxacin susceptibility. There were more .

TỪ KHÓA LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.